Erdafixen Tablets — Erdafitinib 4 mg (28 Tabs) Everest

Prescribed by oncologists for the treatment of adult patients with:

• 🔹 Locally Advanced or Metastatic Urothelial Carcinoma:
  • Patients must have susceptible FGFR3 or FGFR2 genetic alterations as determined by an approved companion diagnostic test.
  • Patients must have progressed during or following at least one line of prior platinum-containing chemotherapy.

Sales Unit: Bottle containing 28 film-coated tablets (4 mg strength).

⚠️ APPLICATION INSTRUCTIONS:

• Starting Dosage: 8 mg (two 4 mg tablets) taken orally once daily.
• Titration: Dosage may be increased to 9 mg based on serum phosphate levels assessed 14 to 21 days after initiating treatment.
• Administration: Swallow tablets whole with water. Can be taken with or without food. Do not chew, crush, or split.
• ✋ Missed Dose: If a dose is missed, take it as soon as possible on the same day. Resume regular schedule the next day. Do not take extra tablets to make up for the missed dose.
• 🤮 Vomiting: If vomiting occurs, do not retake the dose. Wait for the next scheduled dose.

• ⛔ Pregnancy & Breastfeeding: Strictly contraindicated due to embryo-fetal toxicity. Effective contraception is mandatory during treatment.
• Hypersensitivity to Erdafitinib.
• Active central serous retinopathy (CSR) or retinal pigment epithelial detachment (RPED).
• Severe hepatic impairment.

Treatment requires monthly monitoring of serum phosphate levels and regular eye exams. Potential side effects include:

• 🧪 Hyperphosphatemia: Increased phosphate levels in the blood (very common). May require phosphate binders or diet changes.
• 👁️ Ocular Disorders: Blurred vision, dry eyes, risk of retinal detachment. Report vision changes immediately.
• 👄 Stomatitis: Mouth sores, dry mouth.
• 💅 Nail & Skin Toxicity: Nail separation (onycholysis), dry skin, hand-foot syndrome.
• 🚽 Gastrointestinal: Diarrhea, dysgeusia (taste alteration).